About this episode

Fabian Gerlinghaus discusses the challenges and importance of manufacturing living cell therapies at scale in America.

Fabian Gerlinghaus, CEO and Co-Founder of Cellares, joins MFG TMW to discuss what it takes to manufacture living cell therapies at scale — and why doing it in America matters. Cellares operates the world’s first Integrated Development and Manufacturing Organization for automated cell therapy, runs Smart Factories in South San Francisco and Bridgewater, NJ, and recently earned the FDA’s first-ever Advanced Manufacturing Technology designation. We touch on supply chain security, the workforce implications of an 80% reduction in labor requirements, Cellares’ membership in the New American Industrial Alliance, and what its $600M+ in private capital signals about the future of domestic biomanufacturing. A must-listen for anyone thinking about the future of advanced, automated manufacturing. Keywords: Cell therapy manufacturing, automated biomanufacturing, supply chain security, reshoring / domestic manufacturing

People in this episode

Guest: Fabian Gerlinghaus

Topics covered

• cell therapy manufacturing
• automated biomanufacturing
• supply chain security
• workforce implications
• domestic manufacturing

Keywords

• Cell therapy manufacturing
• automated biomanufacturing
• supply chain security
• reshoring
• domestic manufacturing

Mentioned in this episode

Organizations: Cellares, FDA, New American Industrial Alliance

Places: South San Francisco, Bridgewater, NJ

Explore listener stats, chart rankings, contacts and more on the Manufacturing Tomorrow podcast page.